Citeline Provides LEO Pharma with R&D Data via AI Integration

Skip to Content News Archives Economy Defence Energy Oil & Gas Renewables Electric Vehicles Mining Commodities Agriculture Real Estate Mortgages Mortgage Rates Finance Banking Insurance Fintech Cryptocurrency Defence Work Wealth Smart Money Wealth Management Investor Personal Finance Family Finance Retirement Taxes High Net Worth FP Comment Executive Women Puzzmo Newsletters Financial Times Business Essentials More Innovation Information Technology FP500 Podcasts Small Business Lives Told Tails Told Shopping Financial Post Store Obituaries Place a Notice Advertising Advertising With Us Advertising Solutions Postmedia Ad Manager Sponsorship Requests Classifieds Place a Classifieds ad Working Profile Settings My Subscriptions My Offers Newsletters Customer Service FAQ News Economy Energy Mining Real Estate Finance Defence Work Wealth Investor FP Comment Executive Women Puzzmo Newsletters Financial Times Business Essentials This advertisement has not loaded yet, but your article continues below.HomeGlobeNewswireThis section is The content in this section is supplied by GlobeNewswire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by GlobeNewswire Citeline Provides LEO Pharma with R&D Data via AI IntegrationAuthor of the article:How does Pharmaprojects data reveal drug trends, competition and opportunities?THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLYSubscribe now to read the latest news in your city and across Canada.Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.Daily content from Financial Times, the world's leading global business publication.Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.Daily puzzles, including the New York Times Crossword.SUBSCRIBE TO UNLOCK MORE ARTICLESSubscribe now to read the latest news in your city and across Canada.Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.Daily content from Financial Times, the world's leading global business publication.Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.Daily puzzles, including the New York Times Crossword.REGISTER / SIGN IN TO UNLOCK MORE ARTICLESCreate an account or sign in to continue with your reading experience.Access articles from across Canada with one account.Share your thoughts and join the conversation in the comments.Enjoy additional articles per month.Get email updates from your favourite authors.THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.Create an account or sign in to continue with your reading experience.Access articles from across Canada with one accountShare your thoughts and join the conversation in the commentsEnjoy additional articles per monthGet email updates from your favourite authorsSign In or Create an AccountNEW YORK, Oct. 29, 2026 (GLOBE NEWSWIRE) — Citeline, a Norstella company and leading provider of clinical, drug and commercial intelligence for the life sciences industry, continues its partnership with LEO Pharma, a global leader in medical dermatology, to provide pharmaceutical pipeline intelligence.Information on drugs in development is ingested from Citeline’s Pharmaprojects database into LEO Pharma’s proprietary AI tool, the Innoviewer,™ supporting LEO Pharma in monitoring industry competition as well as identifying market opportunities for partnerships, licensing and acquisitions.This advertisement has not loaded yet, but your article continues below.Pharmaprojects contains 90,000 drug profiles — including 20,000 in active development — delivering a complete view of the global R&D pipeline across diseases, drugs, and companies. Spanning the drug development lifecycle from early discovery to launch, Pharmaprojects data also reveals medical device and AI-driven health trends.Get the latest headlines, breaking news and columns.By signing up you consent to receive the above newsletter from Postmedia Network Inc.A welcome email is on its way. If you don't see it, please check your junk folder.The next issue of Top Stories will soon be in your inbox.We encountered an issue signing you up. Please try again“For over forty years, Pharmaprojects has provided the industry with timely, accurate and comprehensive information for drugs in development,” says Suzanne Caruso, President, Citeline Clinical, Regulatory and Strategic Intelligence at Norstella. “Our data is curated by subject-matter experts who not only track trends but analyze them, too. This enables our customers, like LEO Pharma, to make highly informed business decisions. And with our API, we offer a seamless way for customers to integrate our gold-standard data into their own platforms.”“We are pleased to continue our collaboration with Citeline, integrating external data with our internal knowledge about skin biology and dermatology to help power our machine-assisted asset scouting and evaluation,” says Mikkel Lundorf, Digital Lead, External Innovation, LEO Pharma A/S.This advertisement has not loaded yet, but your article continues below.To learn more about Pharmaprojects, visit Citeline.com.Citeline, backed by the strength of Norstella, the AI company for biopharma’s highest-stakes decisions, powers a full suite of complementary business intelligence offerings to meet the evolving needs of life science professionals to accelerate the connection of treatments to patients and patients to treatments. These patient-focused solutions and services deliver and analyze data used to drive clinical-, commercial- and regulatory-related decisions and create real-world opportunities for growth.Citeline’s global teams of analysts, journalists and consultants keep their fingers on the pulse of the pharmaceutical, biomedical and medtech industries, covering them all with expert insights: key diseases, clinical trials, drug R&D and approvals, market forecasts and more. For more information on one of the world’s most trusted health science partners, visit Citeline and follow on LinkedIn and X.Media ContactNorstella@DiffusionPR.com(213) 318-4500This advertisement has not loaded yet.Notice for the Postmedia NetworkThis website uses cookies to personalize your content (including ads), and allows us to analyze our traffic. Read more about cookies here. By continuing to use our site, you agree to our Terms of Use and Privacy Policy.